Prescription Justice heartily endorses Utah bill HB 163, The Prescription Drug Affordability Act, and applauds Utah Representative Norman Thurston (R-63), its lead sponsor. The bill envisions the federal government permitting Utah to import wholesale quantities of FDA-approved drugs from Canada, which would then be dispensed to patients at retail pharmacies and hospitals in Utah. Canadian wholesale pharmacy prices are much lower on many expensive brand name drugs. Utahans would stand to save hundreds of millions of dollars on their collective pharmacy bill.
The bill’s passage would authorize a study, one lead by the Utah Department of Health on the creation of a wholesale drug importation program, one that would operate in accordance with U.S. law. Specifically, Section 804 of the Food, Drug and Cosmetic Act, called Importation of Prescription Drugs, makes wholesale and personal importation of prescription drugs from Canada lawful – but only if the Secretary of Health and Human Services certifies that the practice poses no additional risk to the public’s health and safety and will result in a significant reduction in the cost of covered products to the American consumer. HB 163 endeavors that Utah’s program will receive such certification. (more…)
Prescription Justice recently joined with nine other health, social justice and consumer advocacy organizations to launch a petition to demand Congress act to bring relief to the millions of Americans who can't afford the prescription drugs they need.
The online petition largely echoes the Prescription Justice policy platform which prioritizes ending the ban on Medicare negotiating drug prices, making pay-for-delay deals illegal, and permitting wider access to lower-cost, imported medication through legislative, regulatory, and policy reforms. (more…)
As we leave 2017 behind, the crisis of high prescription drug prices continues to threaten the health and well-being of Americans who struggle to access life-saving medications. Millions of Americans are forced to choose between taking the medicine they need, paying the rent or buying food for their families; tens of millions don't take prescribed medication; and federal and state budgets are overwhelmed. At Prescription Justice, we are dedicated solely to putting an end to this devastating crisis.
Over the past year, we have concentrated our efforts and resources on advocating for regulatory and legislative reforms and commonsense policies to lower domestic drug prices and expand access to lower cost medication from pharmacies in other countries. (more…)
We are pleased to announce that Senator Amy Klobuchar (D-MN) recently introduced legislation aimed at lowering the high cost of prescription drugs for the 41 million seniors enrolled in Medicare. If enacted, S. 1688, The Empowering Medicare Seniors to Negotiate Drug Prices Act, would allow the Secretary of Health and Human Services to negotiate fair prescription drug prices under Part D of the Medicare program. The federal government spends far more on prescription drugs purchased for Medicare enrollees than it spends for Medicaid and the Veterans Administration because the current law prohibits Medicare from negotiating lower prices with pharmaceutical companies.
S. 1688 would eliminate the “non-interference” clause in Title XVIII of the Social Security Act, which expressly bans Medicare from negotiating drug prices. The language in S. 1688 is less restrictive than similar legislation, S. 41, also introduced by Sen. Klobuchar earlier this year. That legislation, S. 41, the Medicare Prescription Drug Price Negotiation Act of 2017, would prohibit the Secretary of Health and Human Services from establishing or requiring a fixed drug formulary for any prescription drug plan in Medicare; S. 1688 wisely omits this binding language.(more…)